Dr Amy Walker joins the board at 4basebio

4basebio is a life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform.

The Cambridge company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

Dr Walker has many years scientific and commercial experience in life sciences, has published scientific papers and is named inventor on numerous multidisciplinary patents. She currently holds non-executive director Board positions on two other high growth healthcare companies.

Last month 4basebio formed a Strategic Advisory Board consisting of Bertrand Coissac, Lawrence Pitcher and Deborah Barbara.

Bertrand Coissac, CEO at Twogene has extensive experience in the life science industry with a focus on cell and gene therapy manufacturing. Before co-founding and leading Twogene, he was Vice President of Corporate Development at Polyplus which was acquired by Sartorius in July 2023.

Lawrence Pitcher is currently the Vice President and General Manager, Maryland Gene Therapy Sites at Catalent Pharma Solutions. He brings significant operational and business experience from his current Catalent role and previous roles at Thermo Fisher Scientific where he was most recently the General Manager of the Advance Therapies business.

Deborah Barbara, former Vice President at Maravai Life Sciences, has over 30 years of life science industry experience in a variety of strategic business and corporate development roles, most recently as Vice President of Strategy and Corporate Development for Maravai Life Sciences. Prior to joining Maravai, she was General Manager of Nucleic Acid Therapeutics business for Thermo Fisher Scientific.